Product Description: Ifabotuzumab (KB004) is an IgG1κ antibody targeting EphA3 (KD=610 pM). Ifabotuzumab induces tumor cell apoptosis, activates Antibody-dependent cell mediated cytotoxicity (ADCC), and damages tumor vasculature. Ifabotuzumab reduces human idiopathic pulmonary fibrosis (IPF) CCR10+ cells and improves pulmonary fibrosis[1][2].
Applications: Cancer-Kinase/protease
Formula: N/A
References: [1]Hohmann MS, et al. Antibody-mediated depletion of CCR10+EphA3+ cells ameliorates fibrosis in IPF. JCI Insight. 2021 Jun 8;6(11):e141061./[2]Swords R T,et al. KB004, a novel non-fucosylated humaneered® antibody, targeting EphA3, is active and well tolerated in a phase I/II study of advanced hematologic malignancies[J]. Blood, 2014, 124(21): 3756.
CAS Number: 2147698-66-4
Molecular Weight: N/A
Compound Purity: 95.0
Research Area: Cancer
Solubility: 10 mM in DMSO
Target: Apoptosis;Ephrin Receptor
English
Deutsch
